Roche's Actemra improves juvenile arthritis symptoms in Phase III
This article was originally published in Scrip
Executive Summary
Roche has released top-line data from a Phase III study of its first-in-class interleukin-6 (IL-6) inhibitor Actemra (tocilizumab) that shows it improves the signs and symptoms of systemic onset juvenile idiopathic arthritis (sJIA) compared with placebo. The company plans to submit data from this trial – known as TENDER – for presentation at an upcoming scientific meeting. Full data and a safety follow-up will used to support global regulatory filings for a sJIA indication.